<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363636</url>
  </required_header>
  <id_info>
    <org_study_id>114-NH-301</org_study_id>
    <nct_id>NCT00363636</nct_id>
  </id_info>
  <brief_title>A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind Study of Galiximab in Combination With Rituximab Compared With Rituximab in Combination With Placebo for the Treatment of Subjects With Relapsed or Refractory, Follicular Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, multicenter, global, clinical study of an investigational drug called&#xD;
      galiximab in combination with an approved drug called rituximab in subjects with follicular&#xD;
      NHL.&#xD;
&#xD;
      The purpose of the study is to compare the clinical benefit of galiximab when given in&#xD;
      combination with rituximab as compared with rituximab alone (given with placebo) in subjects&#xD;
      with follicular NHL. Safety and pharmacokinetics (PK) of galiximab and rituximab will also be&#xD;
      evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment challenges due to changes in standards of care resulted in premature termination. No&#xD;
    safety or efficacy events factored into this action.&#xD;
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess efficacy as measured by progression free survival (PFS), and determine whether rituximab plus galiximab compared to rituximab plus placebo may extend PFS.</measure>
    <time_frame>The duration of this study is approx 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy measures include: event-free survival, time to progression, duration of response, complete response rate, and overall survival.</measure>
    <time_frame>The duration of this study is approx 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measures include: adverse event rates, clinical laboratory results, development of anti-galiximab and human anti-chimeric antibodies.</measure>
    <time_frame>The duration of this study is approx 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>The duration of this study is approx 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using both the Functional Assessment of Cancer Therapy-Lymphoma (FACT-lym) and the EQ-5D (EuroQoL) instruments</measure>
    <time_frame>The duration of this study is approx 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>Lymphoma, Non-Hodgkin's</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galiximab in combination with rituximab</intervention_name>
    <description>Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab in combination with placebo</intervention_name>
    <description>Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Aged &gt;= 18 years old at the time of informed consent.&#xD;
&#xD;
          -  Histologically confirmed follicular Grade 1-3a NHL.&#xD;
&#xD;
          -  Relapsed or progressive disease after at least 1 prior chemotherapy requiring&#xD;
             treatment.&#xD;
&#xD;
          -  Bidimensionally measurable disease with at least 1 lesion &gt;= 2.0 cm in a single&#xD;
             dimension.&#xD;
&#xD;
          -  Acceptable hematologic, hepatic, and renal function parameters.&#xD;
&#xD;
          -  Recovered fully from any significant toxicity associated with prior surgery, radiation&#xD;
             treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell&#xD;
             transplant, or investigational drugs.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Follicular lymphoma Grade 3b.&#xD;
&#xD;
          -  Rituximab refractory or refractory to anti-CD20 radioimmunotherapy (no response to&#xD;
             prior rituximab or prior rituximab-containing regimen, or a response with a TTP of&#xD;
             less than 6 months).&#xD;
&#xD;
          -  Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to Study&#xD;
             Day 1 (6 weeks if nitrosourea or mitomycin C).&#xD;
&#xD;
          -  Prior lymphoma vaccine therapy within 12 months prior to Study Day 1.&#xD;
&#xD;
          -  Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months&#xD;
             prior to Study Day 1.&#xD;
&#xD;
          -  Autologous bone marrow or stem cell transplant within 6 months prior to Study Day 1.&#xD;
&#xD;
          -  Prior allogeneic transplant.&#xD;
&#xD;
          -  Transfusion-dependent subjects.&#xD;
&#xD;
          -  Another primary malignancy requiring active treatment (except hormonal therapy).&#xD;
&#xD;
          -  Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active&#xD;
             uncontrolled bacterial, viral, or fungal infections; or other conditions, which would&#xD;
             compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.&#xD;
&#xD;
          -  New York Heart Association Class III or IV cardiac disease or myocardial infarction&#xD;
             within 6 months prior to Study Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Moldova, Republic of</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>August 11, 2006</study_first_submitted>
  <study_first_submitted_qc>August 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <disposition_first_submitted>September 17, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 17, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 2, 2015</disposition_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed</keyword>
  <keyword>NHL</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>antibody</keyword>
  <keyword>safety</keyword>
  <keyword>galiximab</keyword>
  <keyword>efficacy</keyword>
  <keyword>rituximab</keyword>
  <keyword>refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Galiximab</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

